1, Influenza-like syndrome manifested as fever, headache, myalgia and malaise, etc. IFN-α can be injected at bedtime or antipyretic and analgesic drugs can be taken at the same time of injection. 2, transient peripheral cytopenia absolute neutrophil count ≤ 0.75×109/L and/or platelets < 50×109/L, the dose of IFN-α should be reduced; recheck after 1~2 weeks, if recovery, gradually increase to the original amount. IFN should be suspended for absolute neutrophil count ≤ 0.5×109/L and/or platelets < 25×109/L. For those with significantly lower neutrophils, treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) can be tried. 3. Psychiatric abnormalities can be manifested as depression, delusions, severe anxiety and other psychotic symptoms. For those with severe symptoms, IFN should be discontinued in a timely manner, and if necessary, further consultation with a psychiatrist. Some patients with autoimmune diseases may develop autoantibodies, and only a few patients with thyroid disease, diabetes mellitus, thrombocytopenia, psoriasis, leukoplakia, rheumatoid arthritis and systemic lupus erythematosus-like syndrome, etc. should be consulted and treated together with physicians from relevant departments, and the drug should be discontinued in serious cases. 5, other rare adverse reactions include kidney damage, cardiovascular complications, retinopathy, hearing loss and interstitial pneumonia, etc. Interferon therapy should be stopped.